
Greenwich Lifesciences (GLSI) Stock Forecast & Price Target
Greenwich Lifesciences (GLSI) Analyst Ratings
Bulls say
Greenwich LifeSciences Inc. is advancing its clinical efforts with the GP2 immunotherapy, demonstrating a 100% reduction in recurrence rates among a specific sub-population in the Phase 2 trial, indicative of strong efficacy in preventing breast cancer recurrences. The company is expanding its trial footprint with the European Medicines Agency (EMA) approving the addition of 11 sites across several countries, facilitating increased enrollment and data collection for improved trial results. Despite a net loss of $2.6 million, the consistent alignment with financial estimates and strategic steps toward broader clinical trials provide a solid foundation for a favorable outlook on the company's future growth and financial performance.
Bears say
Greenwich LifeSciences reported a net loss of $2.6 million in the second quarter of 2024, reflecting ongoing financial challenges as the company continues to develop its GP2 immunotherapy. The potential risks associated with GP2 include the possibility of failure in clinical trials, difficulties in securing regulatory approval, and challenges in gaining commercial traction due to market competition and size. Additionally, concerns regarding dilution further exacerbate the negative outlook, indicating potential hurdles to achieving sustainable profitability despite the company’s current clinical advancements.
This aggregate rating is based on analysts' research of Greenwich Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Greenwich Lifesciences (GLSI) Analyst Forecast & Price Prediction
Start investing in Greenwich Lifesciences (GLSI)
Order type
Buy in
Order amount
Est. shares
0 shares